N-methyl-citalopram: A quaternary selective serotonin reuptake inhibitor

Biochemical Pharmacology

Volumn 80, Issue 10, 2010, Pages 1546-1552

  Bismuth Evenzal, Yona ^a   Roz, Netta ^a   Gurwitz, David ^a   Rehavi, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cardiovascular diseases; Citalopram; Human serotonin transporter; Platelets; SLC6A4; SSRI

Indexed keywords

CITALOPRAM; DOPAMINE; KETANSERIN; N METHYL CITALOPRAM; NORADRENALIN; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; N-METHYLCITALOPRAM; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; BRAIN SYNAPTOSOME; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BINDING COMPETITION; BLOOD BRAIN BARRIER; BRAIN CORTEX; CELL MEMBRANE; CHEMICAL STRUCTURE; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOUSE; THROMBOCYTE; THROMBOCYTE AGGREGATION; WISTAR RAT;

ANIMALS; BINDING, COMPETITIVE; BLOOD PLATELETS; BLOOD-BRAIN BARRIER; CELL MEMBRANE; CEREBRAL CORTEX; CITALOPRAM; HUMANS; MALE; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; PLATELET AGGREGATION; PROTEIN BINDING; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 77957018253     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.035     Document Type: Article

References (39)

1. Cerrito F., Lazzaro M.P., Gaudio E., Arminio P., Aloisi G. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci 1993, 53:209-215.
2. Cote F., Fligny C., Fromes Y., Mallet J., Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 2004, 10:232-238.
3. Galan A.M., Lopez-Vilchez I., Diaz-Ricart M., Navalon F., Gomez E., Gasto C., et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost 2009, 102:511-519.
4. Sauer W.H., Berlin J.A., Kimmel S.E. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001, 104:1894-1898.
5. Sauer W.H., Berlin J.A., Kimmel S.E. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003, 108:32-36.
6. Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell Mol Life Sci 2005, 62:159-170.
7. Serebruany V.L., Glassman A.H., Malinin A.I., Atar D., Sane D.C., Oshrine B.R., et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003, 5:517-521.
8. Hergovich N., Aigner M., Eichler H.G., Entlicher J., Drucker C., Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000, 68:435-442.
9. Walther D.J., Peter J.U., Winter S., Holtje M., Paulmann N., Grohmann M., et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 2003, 115:851-862.
10. Atar D., Malinin A., Takserman A., Pokov A., van Zyl L., Tanguay J.F., et al. Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans. J Clin Psychopharmacol 2006, 26:172-177.
11. Halperin D., Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007, 9:47-59.
12. Malinin A.I., Ong S., Makarov L.M., Petukhova E.Y., Serebruany V.L. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract 2006, 60:993-1002.
13. Serebruany V.L., Glassman A.H., Malinin A.I., Nemeroff C.B., Musselman D.L., van Zyl L.T., et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003, 108:939-944.
14. Ho W.K., Hankey G.J., Eikelboom J.W. Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. Expert Opin Pharmacother 2004, 5:493-503.
15. 3H]citalopram binding to brain and platelet membranes of human and rat. J Neurochem 1991, 56:248-252.
16. 3H] imipramine binding in platelets. Biochem Biophys Res Commun 1981, 99:954-959.
17. 3H]desipramine to rat brain: a presynaptic marker for noradrenergic uptake sites. J Neurochem 1982, 38:889-895.
18. Takao K., Nagatani T., Kitamura Y., Yamawaki S. Effects of corticosterone on 5-HT1A and 5-HT2 receptor binding and on the receptor-mediated behavioral responses of rats. Eur J Pharmacol 1997, 333:123-128.
19. Sidman R.L., Angevine J.B., Pierce E.T. Atlas of the mouse brain and spinal cord 1971, Harvard University Press, Cambridge, Mass.
20. Barkan T., Gurwitz D., Levy G., Weizman A., Rehavi M. Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. Eur Neuropsychopharmacol 2004, 14:237-243.
21. Dmitriev A.D., Factor M.I., Segal O.L., Pavlova E.V., Massino Y.S., Smirnova M.B., et al. Western blot analysis of human and rat serotonin transporter in platelets and brain using site-specific antibodies: evidence that transporter undergoes endoproteolytic cleavage. Clin Chim Acta 2005, 356:76-94.
22. Qian Y., Melikian H.E., Rye D.B., Levey A.I., Blakely R.D. Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies. J Neurosci 1995, 15:1261-1274.
23. Rasmussen T.N., Plenge P., Bay T., Egebjerg J., Gether U. A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation. Neuropharmacology 2009, 57:287-294.
24. Kilic F., Rudnick G. Oligomerization of serotonin transporter and its functional consequences. Proc Natl Acad Sci USA 2000, 97:3106-3111.
25. Just H., Sitte H.H., Schmid J.A., Freissmuth M., Kudlacek O. Identification of an additional interaction domain in transmembrane domains 11 and 12 that supports oligomer formation in the human serotonin transporter. J Biol Chem 2004, 279:6650-6657.
26. Ozaslan D., Wang S., Ahmed B.A., Kocabas A.M., McCastlain J.C., Bene A., et al. Glycosyl modification facilitates homo- and hetero-oligomerization of the serotonin transporter. A specific role for sialic acid residues. J Biol Chem 2003, 278:43991-44000.
27. Misra A.L., Pontani R.B., Vadlamani N.L. Intravenous kinetics and metabolism of [15,16-3H]naltrexonium methiodide in the rat. J Pharm Pharmacol 1987, 39:225-227.
28. Ni W., Watts S.W. 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 2006, 33:575-583.
29. Montejo A.L., Llorca G., Izquierdo J.A., Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001, 62(Suppl 3):10-21.
30. Opbroek A., Delgado P.L., Laukes C., McGahuey C., Katsanis J., Moreno F.A., et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?. Int J Neuropsychopharmacol 2002, 5:147-151.
31. Pollock B.G., Laghrissi-Thode F., Wagner W.R. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000, 20:137-140.
32. McCloskey D.J., Postolache T.T., Vittone B.J., Nghiem K.L., Monsale J.L., Wesley R.A., et al. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res 2008, 151:168-172.
33. Benmansour S., Cecchi M., Morilak D.A., Gerhardt G.A., Javors M.A., Gould G.G., et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999, 19:10494-10501.
34. Horschitz S., Hummerich R., Schloss P. Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor. Neuroreport 2001, 12:2181-2184.
35. Nadgir S.M., Malviya M. In vivo effect of antidepressants on [3H]paroxetine binding to serotonin transporters in rat brain. Neurochem Res 2008, 33:2250-2256.
36. Little K.Y., Zhang L., Cook E. Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects. J Psychiatry Neurosci 2006, 31:333-339.
37. Gunther L., Liebscher S., Jahkel M., Oehler J. Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group- and isolation-housed mice. Eur J Pharmacol 2008, 593:49-61.
38. Yamauchi M., Miyara T., Matsushima T., Imanishi T. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res 2006, 1067:164-169.
39. Gomez-Gil E., Gasto C., Carretero M., Diaz-Ricart M., Salamero M., Navines R., et al. Decrease of the platelet 5-HT2A receptor function by long-term imipramine treatment in endogenous depression. Hum Psychopharmacol 2004, 19:251-258.